AGMB FY 2023 Earnings Report — AgomAb Therapeutics N.V. American Depositary Shares Revenue & Financial Results | Market Cap Arena

AgomAb Therapeutics N.V. American Depositary SharesAGMB

FY 2023 Earnings

Reported December 31, 2023

Quarter Comparison

Revenue

Operating Income

EPS (Diluted)

Metric	FY 2023	Prior Q	FY 2022	QoQ Change	YoY Change
Revenue	$0	—	$0	—	—
Op. Income	-$36M	—	-$26M	—	-37.8%
EPS (Diluted)	$-0.36	—	$-0.26	—	-40.9%

Income Statement

Item	Amount
REVENUE	$0
Cost of Revenue	$0
GROSS PROFIT	$0
R&D Expenses	$31M
Selling & Marketing	$0
General & Administrative	$7M
SG&A Expenses	$7M
Other Expenses	-$1M
Operating Expenses	$36M
Cost & Expenses	$36M
OPERATING INCOME	-$36M
Interest Income	$286.4K
Interest Expense	$36.2K
Other Income/Expenses	$22M
INCOME BEFORE TAX	-$14M
Income Tax Expense	-$723.7K
Net Income from Continuing Ops	-$13M
Net Income from Discontinued Ops	$0
Other Adjustments	$0
NET INCOME	-$13M
Net Income Deductions	$0
BOTTOM LINE NET INCOME	-$13M
D&A	$115.7K
EBIT	-$14M
EBITDA	-$14M
EPS	-$0
EPS Diluted	-$0